Scientists investigate with the aim of creating a programmable medication, able to penetrate cancer tumors and destroy them, using the minimum effective dose, and thus avoiding damaging the patient's organs and healthy tissues. One of the main difficulties with which they find themselves in this task is that of designing a particle capable of bypassing the action of the human immune system, and of segregating the adequate quantity of drug in a controlled manner.

Until now, the nanoparticles that had been tried to create for this purpose had not been successful for use in humans. However, in the United States, a group of researchers, specialists in various disciplines, has managed to develop a nanomedicine, called BIND-014, the first of its kind programmed to treat solid tumors in humans that has proven its effectiveness.

BIND-014 is the first of its kind, programmed to treat solid tumors in humans, which has proven its effectiveness

Researchers have proven that BIND-014 is able to reach tumors and release a significant concentration of the anticancer drug inside them, with a greater effectiveness and safety than the chemotherapy drug docetaxel. Dr. Omid Farokhzad, one of the authors of the study, explained that BIND-014 shows that it is possible to create drugs that can be programmed and guided to direct their therapeutic effects directly on the tumor.

The new drug is the first of its kind that has been tested in clinical trials with humans, and scientists have observed that its use resulted in drug concentrations in the tumor ten times higher than those obtained with the usual treatment, and that in many cases the growth of the tumors was stopped, even with doses of medication of only 20% of the one that is generally administered of docetaxel. In addition, BIND-014, in doses of up to 75 mg / m2, has not caused, until now, toxic effects.

Nanomaterials for Cancer therapy (November 2019).